Delivery Order SPE2DB24D2106-SPE2DB25FAVVC
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on September 17, 2025, by the Defense Logistics Agency for Quillivant XR 25 mg/5 ml suspension (120 ml) with a ceiling value of $4,346.15. The contract is a firm fixed-price delivery order with an ultimate completion date of September 18, 2025, and performance will occur in Conshohocken, Pennsylvania. This award was made without a set-aside...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of Quillivant XR 25 mg/5 ml suspension (120 ml) with a ceiling value of $2,217.66. The award, finalized on September 10, 2025, represents a firm fixed-price delivery order with an ultimate completion date of September 11, 2025. Performance will be executed from the vendor's location in Conshohocken, Pennsylvania. This delivery order was...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business located in Park Ridge, Illinois. The contract, valued at $1,314.20, is for the supply of Quillivant XR 25 mg/5 ml suspension (120 ml) and has a period of performance through May 13, 2025. DMS Pharmaceutical Group Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA valued at $499,999,999, which enables the agency to issue...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $1,366.07 contract is for the supply of Quillivant XR 25 mg/5 ml suspension (120 ml) with a performance period ending on May 20, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, enabling the agency to issue delivery orders for a...
- This federal contract award issued by the Defense Logistics Agency (DLA) is a firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $2,537.17 contract is for the supply of Quillivant XR 25 mg/5 ml suspension, a specialized prescription medication. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $1,231.66 by the Defense Logistics Agency on August 12, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities. The contract carries no set-aside designation and is scheduled for completion by August 13, 2025, with performance to take place in Conshohocken, Pennsylvania. This delivery order is issued...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $1,440.48 contract is for the delivery of Quillivant XR 25 mg/5 ml suspension in a 150 ml bottle. The contract has an ultimate completion date of March 3, 2025 and is not associated with any set-aside designation. DMS Pharmaceutical Group Inc. holds a significant $499,999,999 Indefinite Delivery Contract...
- This is a federal contract award from the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $2,973.05, is a firm fixed-price delivery order for Quillivant XR 25 mg/5 ml suspension, a pharmaceutical product. The contract has an ultimate completion date of December 5, 2024. DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical supply chain, providing a range of branded and generic...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract is for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml bottles, with a ceiling value of $2,412.14 and a completion date of July 3, 2025. DMS Pharmaceutical Group Inc. is a pharmaceutical wholesaler based in Park Ridge, Illinois that specializes in providing a range of pharmaceutical products to federal...
- This is a $1,427.36 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is for the supply of Quillivant XR 25 mg/5 ml suspension, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The delivery order is part of a larger Indefinite Delivery Contract (IDC) with DMS Pharmaceutical Group valued at $499,999,999, which allows the DLA to issue...
- SPE2DB24D2106Indefinite Delivery Contract
- SPE2DB24D2106-SPE2DB25FAVVCDelivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois, was awarded a delivery order valued at $1,989.25 by the Defense Logistics Agency (DLA) on July 23, 2025. This firm fixed-price contract calls for the delivery of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities, with performance in Conshohocken, Pennsylvania and an ultimate completion date of July 24, 2025. The award was made without a set-aside designation, allowing the company to compete directly in the federal procurement marketplace. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA valued at $499,999,999 through November 2026, which authorizes the agency to procure a comprehensive range of pharmaceutical products supporting military healthcare facilities worldwide. The company has established itself as a critical supplier in the federal pharmaceutical supply chain, regularly fulfilling delivery orders for prescription medications, biologics, and medical consumables across the Department of Defense healthcare system. Quillivant XR, an extended-release ADHD medication, represents the type of specialized pharmaceutical product that DMS routinely distributes to meet the medical supply needs of military personnel and federal healthcare providers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.0k | 7/23/25 |